利妥昔单抗治疗皮肤B细胞淋巴瘤：两例报告

Rituximab in cutaneous B-cell lymphoma: a report of two cases.

作者信息

Sabroe R A, Child F J, Woolford A J, Spittle M F, Russell-Jones R

机构信息

Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital (GKT), London SE1 7EH, U.K.

出版信息

Br J Dermatol. 2000 Jul;143(1):157-61. doi: 10.1046/j.1365-2133.2000.03607.x.

DOI:10.1046/j.1365-2133.2000.03607.x

PMID:10886152

Abstract

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.

摘要

我们报告了两名原发性皮肤B细胞淋巴瘤患者，他们接受了新型抗CD20单克隆抗体利妥昔单抗的治疗。第一名患者患有小腿弥漫性大B细胞淋巴瘤，病情改善了85%。第二名患者患有原发性皮肤B细胞淋巴瘤，该淋巴瘤已发生高级别转化并出现全身扩散，获得了约30%的轻微缓解。两名患者随后均复发。第一名患者在接受利妥昔单抗联合全身化疗的第二个疗程后实现了完全缓解，但再次复发。据报道，利妥昔单抗治疗复发性系统性低度或滤泡性淋巴瘤的缓解率为48%，但此前尚无利妥昔单抗用于原发性皮肤B细胞淋巴瘤的报道。